ArticleJournal of the National Cancer Institute2015
Interactions Between High- and Low-Risk HPV Types Reduce the Risk of Squamous Cervical Cancer.
Article in Journal of the National Cancer Institute, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Discriminating high-risk cervical Human Papilloma Virus infections with urinary biomarkers via non-targeted GC-MS-based metabolomics.PloS one · 2018Trial
- Correlation between viral load and cervical squamous lesion severity in single and multiple infections: a large-scale analysis.Infectious agents and cancer · 2026Article
- Predicting optimal impact interventions in the post-HPV vaccination world.International journal of cancer · 2026Review
- Determination of Human Papillomavirus prevalence in the female population from Zanjan, Iran.Preventive medicine reports · 2026Article
- Circulating genotypes of human papillomavirus in adult women of reproductive age from the Boeny region of Madagascar: a cross-sectional study to explore needs and opportunities for HPV vaccination in the country.BMC infectious diseases · 2026Article
- Impact of High-Risk HPV Infection on PI3K, MALAT1, H19 and LINC00460 Expression in Cervical Cells.Journal of cellular and molecular medicine · 2025Article
- Detection of Viruses with Oncogenic and Oncomodulatory Potential in Head and Neck Tumors-External Auricle.Biomedicines · 2025Article
- Link between multiple human papillomavirus 16 and 18 infection and prostate cancer, and relevance of tumor characteristics.Molecular and clinical oncology · 2025Article
- Article
- Comparison of Diagnostic Methods in Patients with Squamous Intraepithelial Lesion in Women Infected with Multiple High-Risk Human Papillomaviruses.Iranian journal of pathology · 2025Article
- Risks of Cervical Cancer Recurrence After Fertility-Sparing Surgery and the Role of Human Papillomavirus Infection Types.Journal of clinical medicine · 2024Review
- Patterns of single and multiple HPV infections in female: A systematic review and meta-analysis.Heliyon · 2024Article
- Review
- Structure and transcription of integrated HPV DNA in vulvar carcinomas.NPJ genomic medicine · 2024Article
- Risk of cervical intraepithelial neoplasia grade 3 or more diagnoses for human papillomavirus16/18-positive women by cytology and co-infection status.Infectious agents and cancer · 2023Article
- The cervical microbiota of Hispanics living in Puerto Rico is nonoptimal regardless of HPV status.mSystems · 2023Article
- Splicing Characterization and Isoform Switch Events in Human Keratinocytes Carrying Oncogenes from High-Risk HPV-16 and Low-Risk HPV-84.International journal of molecular sciences · 2023Article
- A Study of Cytokeratin-7 Expression and Clinicopathological Correlation in Dysplasia and Squamous Cell Carcinoma of the Cervix.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination.BMC cancer · 2022Article
- Behavioral factors associated with multiple-type HPV genital infections: data from a cross-sectional study in young women in Brazil.Reproductive health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe clinical significance of co-infections with high-risk (HR) and low-risk (LR) human papillomavirus (HPV) in the etiology of cervical cancer is debated, as prospective evidence on this issue is limited. However, the question is of increasing relevance in relation to HPV-based cancer prevention.
methodsIn two population-based nested case-control studies among women participating in cervical screening with baseline normal smears, we collected 4659 smears from women who later developed cancer in situ (CIS; n = 524) or squamous cervical cancer (SCC; n = 378) and individually matched control subjects who remained free of disease during study follow-up. The median follow-up until diagnosis was 6.4 to 7.8 years. All smears were tested for HPV. We used conditional logistic regression models with two-way interaction terms to estimate relative risks (RRs) for CIS and SCC, respectively. All statistical tests were two-sided.
resultsCompared with women who were infected with HRHPV only, women who were also infected with LRHPV had a lower risk for SCC (RR = 0.2, 95% confidence interval [CI] = 0.04 to 0.99, P = .049). This interaction was not shown for CIS (RR = 1.1, 95% CI = 0.4 to 3.6). Women who were positive for both HRHPV and LRHPV had, on average, a 4.8 year longer time to diagnosis of SCC than women who were positive for HRHPV only (P = .006). Results were highly robust in sensitivity analyses.
conclusionCo-infection with LRHPV is associated with a lower risk of future invasive disease and longer time to diagnosis than infection with HRHPV alone. We propose that co-infection with LRHPV interferes with the rate of progression to invasive cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.